Br
Non vérifié

Brenus Pharma

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueOncologieSantéScience
20/07/2026
Science
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Oncologie
Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension
1.00
02/07/2026
Marché du travail
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member
1.00
27/05/2026
Science
Hygiène alimentaire
Médecine - Divers
Santé Publique
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
Industrie
Événements
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)
1.00
14/04/2026
Événements
Expos
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer
1.00
19/02/2026
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Événements
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026
1.00
12/11/2025
Oncologie
Santé
Science
Santé Publique
Biotechnologie
Événements
Marché du travail
Industrie
Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn
1.00
02/09/2025
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé Publique
Santé
Médecine - Divers
Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy
1.00
19/06/2025
Science
Biotechnologie
Oncologie
Santé
Équipement médical et sanitaire
Santé Publique
Industrie
Événements
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0